The use of immunotherapy for the treatment of both solid and hematologic malignancies is
widespread. Immune checkpoint inhibitors in particular have demonstrated considerable …

Immune-related adverse events (irAEs) are a common occurrence in patients treated with
immune checkpoint inhibitors. Fortunately, the majority of irAEs are mild and easily …

Immune checkpoint inhibitor (ICI) therapy provides a valuable treatment option for many
cancer patients but is associated with immune-related adverse events (irAEs) that can …

With the advent of immunotherapeutic agents, durable and dramatic responses have been
observed in several hard-to-treat malignancies, outlining a roadmap to conquering cancer …

Immune checkpoint inhibitors (ICIs) have revolutionized oncology treatment. However, their
success is mitigated by the recognition that ICI-induced immune-related adverse events …

Abstract Purpose of Review The unleashing of the immune system in an effort to fight cancer
has proven to be an incredible advance in the war on cancer. However that breakthrough …

Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and
programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint …

This chapter provides answers to practice‐based questions with case study covering the
new principles of diagnosis, classification, staging, treatment, and outcomes in identification …

Immune checkpoint inhibitors (anti–cytotoxic T-lymphocyte antigen 4 and anti programmed
cell death 1/programmed cell death 1 ligand antibodies) have shown impressive clinical …

Immunotherapy has heralded the advent of a new era in oncology. Immune checkpoint
inhibitors (ICIs) enhance anti-tumor immunity, thereby reinvigorating a patient's immune …